文献速递神经核医学肿瘤 PET/CT

重建标准化影响[18F]FET PET鉴别胶质瘤进展与治疗相关变化

Reconstruction matters: influence of EARL standards and BSREM in [18F]FET PET for distinguishing glioma progression from treatment-related changes.
PubMed 文献 · EJNMMI Res · 2026-05-29

结果发现不同重建标准下SUV、TBR和BTV存在显著差异,TBRmax鉴别进展与治疗相关变化的AUC均≥0.94但最佳阈值因重建而异,提示需采用重建特异性阈值。

要点

  • EARL2和BSREM150较EARL1得出更高SUV、TBR和BTV,并识别更多可测量病灶。
  • TBRmax鉴别进展与治疗相关变化的AUC≥0.94,但最佳阈值因重建标准而异。
  • 统一阈值跨重建应用有误分类风险,需重建特异性阈值和神经肿瘤专用协调框架。

核心结论

  • 重建标准显著影响[18F]FET PET定量指标和临床判读,跨重建应用统一阈值存在误分类风险。

主要发现

  • EARL2和BSREM150较EARL1得出显著更高的SUV、TBR和BTV,并识别更多可测量病灶。
  • BTV在不同重建间存在差异,将BSREM150分割阈值调整为SUV≥1.7倍平均本底活性可改善BTV一致性并保持更优的可测量病灶检出。
  • TBRmax在所有重建下鉴别进展与治疗相关变化的AUC≥0.94,最佳阈值分别为EARL1 1.67、EARL2 1.84、BSREM150 2.39。
  • 患者水平上EARL1漏诊3例进展,BSREM150将1例治疗相关变化误判为进展。

关键数值与推荐

  • TBRmax鉴别进展与治疗相关变化的最佳阈值:EARL1为1.67,EARL2为1.84,BSREM150为2.39。
  • BSREM150分割阈值调整为SUV≥1.7倍平均本底活性可改善BTV一致性。

临床怎么用

  • 临床判读[18F]FET PET时应使用与重建标准匹配的TBRmax阈值,避免跨重建套用统一阈值。
  • 多中心试验实施PET-RANO时需建立神经肿瘤专用协调框架和重建特异性阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Differentiating progressive disease (PD) from treatment-related changes (TRC) in glioma remains challenging using magnetic resonance imaging (MRI) alone. Amino acid positron-emission tomography (PET) with O-(2-[18F]fluoroethyl)-L-tyrosine ([¹⁸F]FET) is increasingly applied in clinical practice, and the first guideline for PET-based Response Assessment in Neuro-Oncology (PET-RANO) has recently been developed. However, quantitative PET metrics are sensitive to image reconstruction, which may directly influence response classification and clinical interpretation. This study aimed to investigate how different reconstruction standards affect quantitative [¹⁸F]FET PET metrics and to what extent these differences impact clinical interpretation. RESULTS: Thirty-three patients with 42 lesions were analysed. In lesion‑based comparisons, both EANM Research Ltd. harmonization standard version 2.0 (EARL2) and block-sequential regularized expectation maximization using a β-value of 150 (BSREM150) yielded significantly higher standardized uptake values (SUV), tumour‑to‑background ratios (TBR), and biological tumour volumes (BTV) than EANM Research Ltd. harmonization standard version 1.0 (EARL1), and identified a greater number of lesions as measurable disease (MD). BTV differed across reconstructions; adapting the BSREM150 segmentation threshold to SUV ≥ 1.7 x mean background activity improved BTV concordance while preserving superior MD detection. Excellent discrimination between PD and TRC was observed for TBRmax across all reconstructions (area under the curve ≥ 0.94), although optimal thresholds were reconstruction‑specific (EARL1: 1.67; EARL2: 1.84; BSREM150: 2.39). At the patient level, EARL1 failed to identify three PD cases, whereas BSREM150 misclassified one TRC case as PD. CONCLUSION: Reconstruction standards substantially influence quantitative [¹⁸F]FET PET metrics and clinical interpretation. Applying universal thresholds across reconstructions risks misclassification, with EARL1 potentially underestimating tumour extent and BSREM150 increasing false-positive findings. Reconstruction-specific thresholds and neuro-oncology-specific harmonization frameworks are therefore essential for reliable [18F]FET PET assessment in routine clinical practice and PET-RANO implementation in multicentre trials.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. de Jong J, Segbers M, Harteveld AA, et al. Reconstruction matters: influence of EARL standards and BSREM in [18F]FET PET for distinguishing glioma progression from treatment-related changes. EJNMMI Res. 2026. PMID: 42213387. doi:10.1186/s13550-026-01458-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。